CCL20, C-C motif chemokine ligand 20, 6364

N. diseases: 242; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011853
Disease: Diabetes Mellitus, Experimental
Diabetes Mellitus, Experimental 		0.300 Therapeutic disease CTD_human Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. 21340626 2011
CUI: C0011854
Disease: Diabetes Mellitus, Insulin-Dependent
Diabetes Mellitus, Insulin-Dependent 		0.300 Therapeutic disease CTD_human CCL20 peptides, which block CCR6 binding to CCL20, inhibited development of type 1 diabetes. 21340626 2011
CUI: C0020517
Disease: Hypersensitivity
Hypersensitivity 		0.300 Biomarker group CTD_human Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression. 21625544 2011
CUI: C0032285
Disease: Pneumonia
Pneumonia 		0.300 Biomarker disease CTD_human Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression. 21625544 2011
CUI: C0032300
Disease: Lobar Pneumonia
Lobar Pneumonia 		0.300 Biomarker disease CTD_human Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression. 21625544 2011
CUI: C0038433
Disease: Streptozotocin Diabetes
Streptozotocin Diabetes 		0.300 Therapeutic disease CTD_human Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. 21340626 2011
CUI: C0205734
Disease: Diabetes, Autoimmune
Diabetes, Autoimmune 		0.300 Therapeutic disease CTD_human Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. 21340626 2011
CUI: C0342302
Disease: Brittle diabetes
Brittle diabetes 		0.300 Therapeutic disease CTD_human Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. 21340626 2011
CUI: C0887898
Disease: Experimental Lung Inflammation
Experimental Lung Inflammation 		0.300 Biomarker disease CTD_human Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression. 21625544 2011
CUI: C1527304
Disease: Allergic Reaction
Allergic Reaction 		0.300 Biomarker phenotype CTD_human Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression. 21625544 2011
CUI: C3714636
Disease: Pneumonitis
Pneumonitis 		0.300 Biomarker disease CTD_human Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression. 21625544 2011
CUI: C3837958
Disease: Diabetes Mellitus, Ketosis-Prone
Diabetes Mellitus, Ketosis-Prone 		0.300 Therapeutic disease CTD_human Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. 21340626 2011
CUI: C4554117
Disease: Diabetes Mellitus, Sudden-Onset
Diabetes Mellitus, Sudden-Onset 		0.300 Therapeutic disease CTD_human Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. 21340626 2011
CUI: C0274861
Disease: Arsenic Poisoning, Inorganic
Arsenic Poisoning, Inorganic 		0.300 Biomarker disease CTD_human Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population. 16835338 2006
CUI: C0274862
Disease: Nervous System, Organic Arsenic Poisoning
Nervous System, Organic Arsenic Poisoning 		0.300 Biomarker disease CTD_human Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population. 16835338 2006
CUI: C0311375
Disease: Arsenic Poisoning
Arsenic Poisoning 		0.300 Biomarker disease CTD_human Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population. 16835338 2006
CUI: C0751851
Disease: Arsenic Encephalopathy
Arsenic Encephalopathy 		0.300 Biomarker disease CTD_human Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population. 16835338 2006
CUI: C0751852
Disease: Arsenic Induced Polyneuropathy
Arsenic Induced Polyneuropathy 		0.300 Biomarker disease CTD_human Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population. 16835338 2006
CUI: C1257931
Disease: Mammary Neoplasms, Human
Mammary Neoplasms, Human 		0.300 Biomarker disease CTD_human ERE-independent ERalpha target genes differentially expressed in human breast tumors. 16298037 2005
CUI: C4704874
Disease: Mammary Carcinoma, Human
Mammary Carcinoma, Human 		0.300 Biomarker disease CTD_human ERE-independent ERalpha target genes differentially expressed in human breast tumors. 16298037 2005
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.300 Biomarker disease CTD_human Global gene expression analysis of rat colon cancers induced by a food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. 15059925 2004
CUI: C0009375
Disease: Colonic Neoplasms
Colonic Neoplasms 		0.300 Biomarker group CTD_human Global gene expression analysis of rat colon cancers induced by a food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. 15059925 2004
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy 		0.220 Biomarker disease BEFREE Targeting pro-inflammatory chemokine MIP-3α and its signaling pathways will provide novel strategy to treat diabetic kidney disease. 21109018 2011
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy 		0.220 Biomarker disease RGD In summary, we have uniquely demonstrated that high glucose increases MIP-3 alpha through a TGF beta 1 dependent pathway, suggesting the centrality of TGF-beta1 in both the inflammatory and previously demonstrated fibrotic responses in diabetic nephropathy. 17664181 2007
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy 		0.220 Biomarker disease BEFREE In summary, we have uniquely demonstrated that high glucose increases MIP-3 alpha through a TGF beta 1 dependent pathway, suggesting the centrality of TGF-beta1 in both the inflammatory and previously demonstrated fibrotic responses in diabetic nephropathy. 17664181 2007